[1]Olivieri F, Capri M, Bonafe M, et al. Circulating miRNAs and miRNA shuttles as biomarkers: Perspective trajectories of healthy and unhealthy aging[J]. Mech Ageing Dev, 2017,165(Pt B):162–170.
[2]Xu X M, Zhang H J. miRNAs as new molecular insights into inflammatory bowel disease: Crucial regulators in autoimmunity and inflammation[J]. World J Gastroenterol, 2016,22(7):2206–2218.
[3]Qadir M I, Faheem A. miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer[J]. Crit Rev Eukaryot Gene Expr, 2017,27(3):197–204.
[4]Huang Z, Zhu D, Wu L, et al. Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer[J]. Cancer Epidemiol Biomarkers Prev, 2017,26(2):188–196.
[5]Kekomaki S, Hamalainen L, Kauppinen-Makelin R, et al. Genetic polymorphism of platelet glycoprotein IIIa in patients with acute myocardial infarction and acute ischaemic stroke[J]. J Cardiovasc Risk, 1999,6(1):13–17.
[6]Gu L, Su L, Chen Q, et al. Association between the apolipoprotein E gene polymorphism and ischemic stroke in Chinese populations: New data and meta-analysis[J]. Exp Ther Med, 2013,5(3):853–859.
[7]Ariyaratnam R, Casas J P, Whittaker J, et al. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals[J]. PLoS Med, 2007,4(4):e131.
[8]Ma W Q, Qu Q R, Zhao Y, et al. Association of RAGE gene Gly82Ser polymorphism with coronary artery disease and ischemic stroke: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2016,95(49):e5593.
[9]Miao L, Yin R X, Yang S, et al. Association between single nucleotide polymorphism rs9534275 and the risk of coronary artery disease and ischemic stroke[J]. Lipids Health Dis, 2017,16(1):193.
[10]Jeon Y J, Kim O J, Kim S Y, et al. Association of the miR–146a, miR–149, miR–196a2, and miR–499 polymorphisms with ischemic stroke and silent brain infarction risk[J]. Arterioscler Thromb Vasc Biol, 2013,33(2):420–430.
[11]Xiao Y, Bao M H, Luo H Q, et al. A Meta-Analysis of the Association between Polymorphisms in MicroRNAs and Risk of Ischemic Stroke[J]. Genes (Basel), 2015,6(4):1283–1299.
[12]Darabi H, Salmaninejad A, Jaripour M E, et al. Association of the genetic polymorphisms in immunoinflammatory microRNAs with risk of ischemic stroke and subtypes in an Iranian population[J]. J Cell Physiol, 2019,234(4):3874–3886.
[13]Zhu J, Yue H, Qiao C, et al. Association Between Single-Nucleotide Polymorphism (SNP) in miR–146a, miR–196a2, and miR–499 and Risk of Ischemic Stroke: A Meta-Analysis[J]. Med Sci Monit, 2015,21:3658–3663.
[14]http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp[EB/OL].
[15]Egger M, Davey S G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test[J]. BMJ, 1997,315(7109):629–634.
[16]Huang S, Zhou S, Zhang Y, et al. Association of the genetic polymorphisms in pre-microRNAs with risk of ischemic stroke in a Chinese population[J]. PLoS One, 2015,10(2):e117007.
[17]Liu Y, Ma Y, Zhang B, et al. Genetic polymorphisms in pre-microRNAs and risk of ischemic stroke in a Chinese population[J]. J Mol Neurosci, 2014,52(4):473–480.
[18]Luo H C, Luo Q S, Wang C F, et al. Association of miR–146a, miR–149, miR–196a2, miR–499 gene polymorphisms with ischemic stroke in a Chinese people[J]. Oncotarget, 2017,8(46):81295–81304.
[19]Zhu X, Hou R, Ma A, et al. Associations of miR–146a, miR–149, miR–196a2, and miR–499 Polymorphisms with Ischemic Stroke in the Northern Chinese Han Population[J]. Med Sci Monit, 2018,24:7366–7374.
[20]Zou D, Liu C, Zhang Q, et al. Association between polymorphisms in microRNAs and ischemic stroke in an Asian population: evidence based on 6,083 cases and 7,248 controls[J]. Clin Interv Aging, 2018,13:1709–1726.
[21]Wang J X, Jiao J Q, Li Q, et al. miR–499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein–1[J]. Nat Med, 2011,17(1):71–78.
[22]Yang B, Chen J, Li Y, et al. Association of polymorphisms in pre-miRNA with inflammatory biomarkers in rheumatoid arthritis in the Chinese Han population[J]. Hum Immunol, 2012,73(1):101–106.
[23]Cattin L, Da C P, Feruglio F S, et al. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study[J]. Clin Ther, 1990,12(6):482–488.